Table 1. Patient and tumour characteristics at baseline.
| Aflibercept, 4 mg kg−1, n=6 | Aflibercept, 5 mg kg−1, n=7 | Aflibercept, 6 mg kg−1, n=17 | Aflibercept, all, n=30 | |
|---|---|---|---|---|
| Gender, female, n (%) | 6 (100.0) | 7 (100.0) | 8 (47.1) | 21 (70.0) |
| Median age, years (range) | 52.5 (45–69) | 53.0 (39–58) | 57.0 (27–76) | 53.5 (27–76) |
| ECOG performance status, n (%) | ||||
| 0 | 2 (33.3) | 7 (100.0) | 7 (43.8) | 16 (55.2) |
| 1 | 4 (66.7) | 0 | 9 (56.3) | 13 (44.8) |
| Primary tumour site, n (%) | ||||
| Breast | 3 (50.0) | 2 (28.6) | 2 (11.8) | 7 (23.3) |
| Ovary | 3 (50.0) | 2 (28.6) | 1 (5.9) | 6 (20.0) |
| Colon | 0 | 1 (14.3) | 3 (17.6) | 4 (13.3) |
| Sarcoma | 0 | 0 | 4 (23.5) | 4 (13.3) |
| Rectum | 0 | 0 | 2 (11.8) | 2 (6.7) |
| Othera | 0 | 2 (28.6) | 5 (29.4) | 7 (23.3) |
| Median number of organs involved (range) | 2.5 (1–4) | 2.0 (1–6) | 2.0 (1–5) | 2.0 (1–6) |
| Prior surgery, n (%) | 6 (100.0) | 7 (100.0) | 14 (82.4) | 27 (90.0) |
| Prior radiotherapy, n (%) | 3 (50.0) | 3 (42.9) | 6 (35.3) | 12 (40.0) |
| Prior chemotherapy, n (%) | 6 (100.0) | 7 (100.0) | 16 (94.1) | 29 (96.7) |
| Median number of lines of prior chemotherapy (range) | 4.0 (3–4) | 4.0 (2–4) | 2.5 (1–5) | 4.0 (1–5) |
| Prior taxane therapy, n (%) | 6 (100.0) | 4 (57.1) | 5 (29.4) | 15 (50.0) |
| Prior platinum therapyb, n (%) | 4 (66.6) | 4 (57.1) | 2 (11.8) | 10 (33.3) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
a
Including cancers of the cervix, oesophagus, eye, lung, other female genital organs, pancreas, and pleura.
b
Cisplatin or carboplatin.